Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2024年7月4日
	新闻
	Roche to Halt Lung Cancer Drug Study in Fresh Setback - SWI swissinfo.ch Swissinfo (Bloomberg) — Roche Holding AG will halt a study of a potential blockbuster drug after it performed worse than existing therapy in lung cancer, ... 标记为不相关
	Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer Nature Small-cell lung cancer (SCLC) has traditionally been considered a recalcitrant cancer with a dismal prognosis, with only modest advances in ... 标记为不相关
	Ociperlimab by BeiGene for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology ... Lung Cancer. According to GlobalData, Phase I drugs for Squamous Non-Small Cell Lung Cancer have an 89% phase transition success rate (PTSR) ... 标记为不相关
	MCLA-145 by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval Pharmaceutical Technology ... cancer, anal cancer ,gastric cancer ,merkel cell carcinoma ,lung cancer ,colorectal cancer, pancreatic cancer and B-cell lymphomas. The ... 标记为不相关
	ADCs: The New Frontier in Cancer Treatment - Pharmacy Times Pharmacy Times Antibody-drug conjugates (ADCs) revolutionize cancer therapy by delivering powerful drugs directly to tumors and minimize damage to healthy cells. 标记为不相关
	Comprehensive analysis of PPP4C's impact on prognosis, immune microenvironment, and ... Frontiers Lung adenocarcinoma (LUAD), a prevalent form of lung cancer, remains a leading cause of cancer-associated mortality globally (1), displaying a ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈